

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA

IN RE: AFLIBERCEPT PATENT
LITIGATION

Master Case No: 1:24-md-3103-TSK
MDL 3103

THIS DOCUMENT RELATES TO ALL CASES

REGENERON PHARMACEUTICALS, INC.,
Plaintiff,

v.

CIVIL NO. 1:23-CV-89

CELLTRION, INC.,
Defendant.

v.

CIVIL NO. 1:23-CV-94

SAMSUNG BIOEPIS, CO., LTD.,
Defendant.

v.

CIVIL NO. 1:23-CV-97

FORMYCON AG,
Defendant.

v.

CIVIL NO. 1:23-CV-106

SAMSUNG BIOEPIS, CO., LTD.,
Defendant.

v.

CIVIL NO. 1:22-CV-61

MYLAN PHARMACEUTICALS INC. and
BIOCON BIOLOGICS INC.
Defendants.

ORDER CONTINUING MAY 2, 2024 PERMANENT AND PRELIMINARY
INJUNCTION HEARINGS

On January 9, 2024, the Court scheduled hearings regarding

Plaintiff Regeneron Pharmaceuticals, Inc.'s preliminary and permanent injunction motions against the above-named Defendants for May 2, 2024. On April 11, 2024, the Aflibercept Patent Litigation [MDL No. 3103] was transferred to this Court, consolidating six actions to resolve common factual and legal questions. ECF No. 1, 24-md-03103. Additionally, the Court is expected to be in a criminal jury trial on May 2, 2024.

Given the multi-district litigation consolidation, as well as the scheduled criminal trial, the Court **CONTINUES** the May 2, 2024 hearing. The Court will reschedule the preliminary and permanent injunction hearings, if necessary, by separate order. For reasons stated herein, the parties' *Joint Motion for Status Conference Regarding the May 2, 2024 Permanent and Preliminary Injunction Hearings* is also **DENIED** [ECF No. 9].

It is so **ORDERED**.

The Clerk is **DIRECTED** to transmit copies of this Order to counsel of record.

DATED: April 24, 2024



THOMAS S. KLEE, CHIEF JUDGE
NORTHERN DISTRICT OF WEST VIRGINIA